Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Biologics & biosimilars - Prof Bjørn Moum - April 5th 2016

652 views

Published on

Prof Bjorn Moum of Oslo University Hospital Ulleval, Norway provides an international perspective on biologic & biosimilar medicines.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Biologics & biosimilars - Prof Bjørn Moum - April 5th 2016

  1. 1. Experience with biosimilars in Norway The Oslo University Hospital Experience Bjørn Moum Professor Department of Gastroenterology Oslo University Hospital
  2. 2. Current Resources used in IBD after 2000 Therapeutic Approach to IBD 2012 2014 18% -> 20%
  3. 3. Biologicals & Biosimilars N: • 1st Biologicals for IBD available in 2000 • Approval 1st biosimilar 28th Feb 2014
  4. 4. Tidsskir Nor Legeforen nr, 8, 2014: 134:819-20
  5. 5. Tidsskir Nor Legeforen nr, 8, 2014: 134:819-20
  6. 6. Department of gastroenterology at OUS - 2014 • 14,000 outpatient contacts • 9000 endoscopies : • 3500 : - Day care unit 250 inf /mths (3000/yr) - IBD - IBD consultations ++
  7. 7. Biologicals & Biosimilars N: «History» Approval 1st biosimilar 28th Feb 2014 • LIS* price NOK 89.000 (Remsima®): 39% reduction to originator infliximab (Remicade®) • LIS price 26th Feb 2015 NOK 43 000 (79% reduction) • LIS price 28th Feb 2016 NOK 62 000 (+40% increase Remsima) NOK 50 000 (- 20% reduction Inflectra) * LIS - Drug procurement cooperation
  8. 8. Biologicals & Biosimilars: OUS (Ullevaal) Department of Gastroenterolgy • NOR Switch started May 2014 • All new IBD patients Remsima - • All IBD patients switched from Remicade to Remsima Sept 2015 – • Switching om medical reasons - Remsima (Stable adalimumab patients continue adalimumab)
  9. 9. Biologicals & Biosimilars: OUS (Ullevaal) Department of Gastroenterolgy 2014 IFX: 4 mill Euro year 2014 IFX: (39% discount) 2015 Sept: (79% discount & shifting!) • Switching to biosimilar IFX= savings 1.7 mill Euro • adalimumab 160 pts: 2.7 mill Euro o biosimilars to adalimumab expected 2018
  10. 10. Biologicals & Biosimilars: OUS (Ullevaal) Department of Gastroenterolgy • Switching to biosimilar = savings: 1.7 mill Euro • Negotiated gain share to improve IBD service and improve patient care/quality assure Aug 2015: – One extra clinician employed 2015/2016 – One IBD nurse employed 2015/2016
  11. 11. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Remsima marketshare
  12. 12. Clinical consequences introducing biosimilars • More patients introduced to biologicals; moderate disease. • Patients introduced to biologicals earlier (even before steroids; change the disease course; prevent complications) • Patients will have intensified dosage (high inflammatory burden, overcome neutralizing antibody formation -> preventing loss off response) • Patients on biological combination treatment (TNFalfa and α4β7-integrin) • Patients not stopping biologics on economic reasons
  13. 13. • If switching to the cheaper biosimilar leads to more patients on biologics, who will end up with these costs? • Not only the pure costs of medicine, but also need for equipment, rooms, medical staff • Will the reduced price by originator to match biosimilar, put the biosimilar out of business? • Will reduced price affect funding for innovative therapy from big pharma? Future Questions
  14. 14. • Have come to stay • Safe …. so far • Resources saved • More biosimilars -> compexity • Future ……? Conclusion - biosimilars
  15. 15. • more biosimilars expected (adalimumab in 2018) • ‘biogenerics‘ erythropoietin obtained by complete chemical synthesis recently • ‘biobetter’ • ‘biosuperiors’ • second generation biologics The Future

×